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Abstract 
Systemic sclerosis (SSc) is a devastating chronic autoimmune connective tissue disease characterized 
by vasculopathy, autoimmunity with inflammation and progressive fibrogenesis. The current paradigm of 
the pathogenesis of SSc is that of an unknown initial trigger, leading to a complex interaction of immune 
cells, endothelial cells and fibroblasts, producing cytokines, growth and angiogenic factors, resulting in 
uncontrolled and persistent tissue fibrogenesis by an altered mesenchymal cell compartment. Animal 
models are of utmost importance to investigate the different steps in the pathogenesis. This review will 
elaborate on recent findings in established and more recently developed animal models, presenting data on 
compounds that are in or ready to be translated into clinical trials, or provide interesting new findings in the 
understanding of the pathophysiology of SSc. We focus on recent findings concerning the vessel – 
extracellular matrix interaction, the initial triggering aggressor, the concept of autoimmunity and 
inflammatory changes, the effector cells and their origins and the complex interaction of the different 
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Introduction  
Systemic sclerosis (SSc) is a severe, chronic connective tissue disease, characterized by vasculopathy, 
inflammation with features of autoimmunity and progressive fibrosis (1). A deregulated fibroblast 
compartment produces and deposits increased amounts of extracellular matrix (ECM), resulting in 
progressive fibrosis of skin and internal organs, leading to tissue damage and organ failure. SSc remains a 
challenging disease with a highly variable clinical course and lack of effective therapy options, making it 
one of the top research priorities in the field of systemic rheumatic diseases.  
Fibrosis is the hallmark feature of SSc. The imbalance in deposition and degradation of the ECM 
components is often considered the ominous result of an initial attempt for regeneration or wound healing 
that lacks successful confinement and termination of the process (2).  The current paradigm of the 
pathogenesis of SSc is a multistep process where an unknown initial trigger leads to a complex interaction 
of immune cells, endothelial cells and fibroblasts, with production of cytokines, growth and angiogenic 
factors, resulting in uncontrolled and persistent tissue fibrogenesis by a modified mesenchymal cell 
compartment. 
The ideal animal model for human SSc should therefore encompass and integrate all features of the disease 
including vasculopathy, autoimmunity with production of autoantibodies and progressive fibrosis. 
However, this phenocopy is yet to be described. Nevertheless, several murine models are available and can 
be used to study aspects of the human disease. This review will highlight a selection of recent findings in 
established and more recently developed animal models, that either present data on compounds that are in 
or ready to be translated into clinical trials, or provide interesting new findings in the understanding of the 
pathophysiology of SSc.  
A focus on vessel – extracellular matrix interaction 
Microangiopathy with endothelial damage and perivascular inflammation is an early phenomenon in SSc 
patients (3, 4). The current paradigm suggests that the resulting uncontrolled repair processes culminate in 
intimal proliferation and adventitial fibrosis of the vessel, with subsequent luminal obliteration causing 
tissue hypoxia, ischemia and potentially necrosis (5). It is currently unclear whether the initial vessel injury 
is a toxic, metabolic or autoimmune event and the primacy of vascular injury or autoimmunity in the 
disease has not been established. New animal models show both vasculopathy and skin and/or lung fibrosis, 
and are therefore promising tools to study the complex cell and tissue crosstalk that characterizes onset and 
progression of disease. A series of genetic mouse models has identified potential key players in these 
processes that fit into a rapidly developing network of cell-matrix interactions, that have been validated in 
SSc patient tissues and appear strongly regulated by epigenetic factors in the patient population. 
Fra-2 transgenic mice 
Fra-2 is a signaling molecule from the Fos protein family. Fos proteins (c-Fos, FosB, Fra-1 and Fra-2) form 
the transcription factor complex AP-1 together with Jun proteins (c-Jun, JunB and JunD). AP-1 activity 
controls different cell stress responses including inflammation, proliferation, apoptosis, carcinogenesis and 
wound healing. The serendipitous observation that Fra-2 transgenic mice develop fibrosis, primarily in the 
lung but also in other organs, sparked interest in its role in SSc (6). Effectively, Fra-2 positive endothelial 
and vessel-associated smooth muscle cells were found in the affected skin of SSc patients and clearly 
increased compared to healthy skin (7).  
The Fra-2 transgenic mice, in which the murine Fra-2 gene is expressed under the control of the ubiquitous 
major histocompatibility complex class I antigen H2Kb promoter are viable and fertile but die at the age of 
17 weeks in respiratory distress. Increased collagen deposition is observed in the lungs, skin, thymus, heart 
and gastrointestinal system. At the age of 12 weeks, obliteration and neo-intima formation with 
perivascular inflammation are observed in pulmonary arteries. These vascular changes precede the fibrotic 
changes by 2-3 weeks, the latter characterized by interstitial lymphocytic inflammation with excessive 
collagen deposition and the appearance of structures resembling fibroblast foci and peripheral 
honeycombing changes. These findings positioned the Fra-2 transgenic mice as a model for SSc-associated 
pulmonary hypertension and fibrosis (8).  In the skin, vasculopathy with perivascular infiltrates and 
endothelial apoptosis results in a progressive decrease in dermal capillary density further evolving into 
fibrosis. Notably, there was no evidence for proliferative vasculopathy in the skin (7). Fra-2 transgenic 
mice also show cardiac changes with endothelial cell apoptosis, reduced capillary density, perivascular 
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inflammation, myofibroblast differentiation, and myocardial accumulation of collagen, comparable to the 
changes observed in SSc patients (9). Further analysis of the pulmonary vascular changes in Fra-2 
transgenic mice showed a link between arterial remodeling, increased vessel wall thickness, occlusion of 
pulmonary arteries and increased vascular expression of platelet-derived growth factor (PDGF)-BB and its 
receptor PDGF-Receptor-b. Of translational interest, pulmonary arterial remodeling and fibrosis 
development were successfully inhibited in this model by inhibition of the PDGF receptor using tyrosine 
kinase antagonist nilotinib (8).   
The effects of Fra-2 are mainly due to abnormalities in the endothelial and mesenchymal cells: 
hematopoietic cells do not appear to contribute to lung fibrosis development in this model, as no pulmonary 
fibrosis is observed in wild type mice reconstituted with Fra-2 transgenic bone marrow. Pulmonary fibrosis 
also develops to equal extent in Fra-2tg/Rag2-/- mice, indicating that the development of lung fibrosis in this 
model does not require functional B- or T-cells. The fibrotic response is characterized by an increased 
number of myofibroblasts with evidence for epithelial-to-mesenchymal transition (EMT) and enhanced 
expression of profibrotic cytokines (interleukin (IL)-2, IL-4 and IL-6).  Of note, no SSc-specific 
autoantibodies are detected (6).  How Fra-2 gets activated in SSc patients is currently unclear but there is 
evidence that its expression is affected by epigenetic mechanisms. Inhibition of histone 3 lysine 27 
(H3K27) histone trimethylation induces the expression of Fra-2, resulting is “spontaneous” skin fibrosis 
and exacerbated fibrosis when induced by bleomycin or by overexpression of a constitutively active 
transforming growth factor β receptor type I (TβRICA) (10). In conclusion, Fra-2 transgenic mice develop 
dermal and pulmonary vasculopathy preceding the onset of skin and lung fibrosis, and cardiac changes 
closely resembling human SSc. Fra-2 might therefore be an interesting novel candidate for molecular-
targeted therapies for SSc. 
Urokinase-type plasminogen activator receptor (uPAR)-/- mice  
The fibrinolytic system consists of serine proteases that play a crucial role in ECM degradation. uPAR is 
key component in this process as it  concentrates the enzymatic activity of its ligand uPA (urokinase) at the 
cell-matrix interface. There is evidence that uPAR is implicated in the pathogenesis of SSc. A single 
nucleotide polymorphism located in the promoter region of the uPAR (CD87) gene is a risk factor for SSc 
vasculopathy (digital ulceration and pulmonary arterial hypertension (PAH)) (11). Levels of uPAR are 
lower in SSc skin compared to healthy controls. Mice with targeted deletion of the uPAR gene were 
generated, resulting in complete uPAR deficiency (12). From 12-24 weeks of age onwards, profibrotic 
cytokines are upregulated (transforming growth factor β (TGFβ), connective tissue growth factor (CTGF), 
endothelin-1 (ET-1)), resulting in increased dermal thickness with perivascular fibrosis and lipoatrophy. 
Inflammatory infiltrates are observed as clustered degranulating mast cells in the deeper dermal layers, 
most prominent in 12-week old mice. Dermal vasculopathy is evident with decreased microvascular density 
and higher number of apoptotic endothelial cells. No intimal proliferation is observed. Between 12 and 24 
weeks of age, the lungs of uPAR-/- mice show progressive cellular infiltration and collagen deposition. 
However, no evidence for pulmonary angiopathy is detected. So uPAR-/- mice are presented as a murine 
SSc model with peripheral small vessel vasculopathy and progressive skin and lung fibrosis (13).  
Fli1 mutant mice  
Fli1 is a transcription factor that plays a crucial role in hematopoiesis and megakaryocyt formation (14). In 
healthy human skin Fli1 protein is expressed in fibroblasts and endothelial cells and functions as a 
transcriptional repressor of collagen 1a2 (Col1a2) expression (15). In affected skin of SSc patients, Fli1 
expression is reduced in endothelial cells (16) and epigenetically repressed in fibroblasts (17). It was 
demonstrated that TGFβ acetylates Fli1 in dermal fibroblasts, leading to the dissociation of Fli1 from the 
collagen and CTGF promoter associated with up-regulation of Col1a1 and Col1a2 genes and down-
regulation of the matrix metalloproteinase 1 (MMP1) gene (18). Fli1-/- mice are embryonically lethal and 
die in utero at E11 due to cranial and spinal hemorrhage (19).  
The C-terminal transcriptional activator (CTA) domain of the Fli1 gene can function either as a 
transcriptional activator or repressor (20).  To further study the role of Fli1 in collagen expression, mice 
with a targeted deletion of the CTA domain were generated (Fli1ΔCTA) (21).   The skin of Fli1ΔCTA mice 
had a normal dermal thickness, but had abnormal collagen fibrils with an abnormal wide range of fibril 
diameter and enhanced Col1a2 expression (22). Albeit that the skin phenotype of these mice is clearly 
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different from that of SSc patients, the described abnormalities in this mouse model demonstrate the critical 
role of this gene in homeostasis of the skin. The reduced levels of Fli1 in SSc endothelial cells stimulated 
further research into the potential role of Fli1 in SSc vasculopathy. For this purpose, mice with a 
conditional deletion of Fli1 in endothelial cells (Fli1 CKO) were generated. Mice with Cre recombinase 
under the control of the endothelium specific Tie2 (Tek) receptor promoter were crossed with Fli1flox/flox 
mice. Fli1 CKO showed a disorganized dermal vascular network with compromised vessel integrity 
including micro-aneurysmata and dilated capillaries, and markedly increased vessel permeability, 
recapitulating some aspects of the pathological SSc microvasculature. Expression levels of VE-cadherin, 
platelet endothelial cell adhesion molecule 1 (PECAM1), type IV collagen, MMP9, PDGF-B, and S1P(1) 
receptor were regulated by Fli1, pointing at a role of Fli1 as a regulator of vessel maturation and 
stabilization. It is therefore hypothesized that reduced levels of Fli1 in endothelial cells play a critical role 
in the development of SSc vasculopathy (23). Bleomycin-treated Fli1 haploinsufficient mice recapitulate 
most SSc features with dermal fibrosis, inflammation and vascular activation. They show increased dermal 
fibrosis, via the up-regulation of αvβ3 and αvβ5 integrins and activation of latent TGFβ as compared to 
wild-type control mice. 
Vascular endothelial growth factor (VEGF) overexpression mice 
SSc patients are characterized by the presence of high levels of VEGF in serum (24) and skin (25), albeit 
with defective angiogenesis. Recent data suggest a novel direct role for VEGF in fibrogenesis, providing a 
molecular link between vasculopathy and fibrosis (26).  Double (+/+) VEGF transgenic (tg) mice 
spontaneously develop skin fibrosis from 10 weeks onwards, with evidence of proliferative dermal 
vasculopathy. VEGF-tg mice have exaggerated fibrotic responses, both in the bleomycin model, modeling 
the early, inflammatory stages of the disease and the tight skin 1 (Tsk1) mouse, mimicking later non-
inflammatory stages of SSc (26). It is not clear if upregulation of VEGF is an intrinsic part of disease or 
rather a compensatory consequence of vessel abnormalities in SSc with undesired negative effects on 
fibrogenesis. 
Targeting the aggressor 
Potential aggressors leading to vascular or epithelial damage as initiating events in SSc pathogenesis are 
still debated. Oxidative stress is put forward as a potential key player as SSc fibroblasts produce large 
amounts of reactive oxygen species (ROS) and this feature is associated with increased collagen synthesis 
(27). ROS production can also be linked to SSc vasculopathy as repetitive ischemia-reperfusion cycles 
typically generate superoxide anions (28).  Some existing mouse models provide further support for these 
observations. Daily subcutaneous injections of specific ROS-generating solutions for 6 weeks in the shaved 
back skin of 6-week-old mice can reproduce both diffuse (dcSSc) and limited (lcSSc) cutaneous SSc (29). 
Hypochlorous acid (HOCl)-induced fibrosis is another model of SSc in which repeated intradermal 
injections of HOCl mirror dcSSc with skin and lung fibrosis, renal arteriopathy and the presence of human 
disease associated antitopoisomerase-I antibodies (29). Skin involvement is characterized by increased 
dermal thickness, collagen content and fibroblast proliferation rate. In the lung thickened interalveolar 
septae, increased collagen content and T-cell infiltrates are observed. HOCL resulted in collagen 
accumulation in the renal interstitium and arteriopathy with intima/media thickening. Advanced oxidation 
protein products (AOPP), generated from DNA topoisomerase I (induced by HOCL) may link dermal and 
lung fibrosis in this model as serum AOPP concentrations were elevated in the dcSSc model and are 
present at increased levels in dcSSc patients. Experiments in severe combined immunodeficiency (SCID) 
mice show that a functional immune system is not required for the induction of skin fibrosis but is however 
required for full development of lung fibrosis. This model appears also amenable for therapeutic 
intervention. For instance treatment with simvastatin, a lipid-lowering drug that inhibits cholesterol 
synthesis prevented both dermal and pulmonary fibrosis (30). Interestingly, repeated intradermal injections 
of peroxynitrite (ONOO-) resulted in dermal fibrosis and the presence of human disease associated anti-
centromere antibodies (anti-CENP-B), however without evidence of systemic manifestations, therefore 
mirroring lcSSc (29).   
Increased ROS levels are linked to damage and the initiation of fibrogenesis. However, when ROS levels 
are increased beyond a lethal, cytotoxic threshold, they could be used to selectively kill activated 
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fibroblasts and therefore applied therapeutically. The organo-tellurium-based catalyst 2,3-
bis(phenyltellanyl)naphthoquinone ((PHTE)(2)NQ) was shown to prevent HOCl-induced murine systemic 
sclerosis with reduced levels of AOPP and antitopoisomerase-I antibodies, due to the selective pro-
oxidative and cytotoxic effects of (PHTE)(2)NQ on hyperproliferative fibroblasts (31). Similarly, treatment 
with arsenic trioxide (As(2) O(3)) reduced dermal fibrosis in the HOCL model, abrogated vascular damage 
and inhibited autoantibody production through ROS-dependent killing of activated fibroblasts containing 
low levels of glutathione (32).  
Autoimmunity and inflammatory changes  
The role of autoimmunity as a primary or secondary event in the pathogenesis of SSc remains elusive. The 
presence of autoantibodies, different genetic associations with key molecules in the immune system and the 
recognition of inflammation in tissue biopsies are counterbalanced by the limited effects of broad 
immunosuppressive strategies. The current paradigm of SSc proposes that activation of the innate immune 
system influences adaptive immune responses and drives T-cell polarization following the lines of a 
classical immune reaction (33). Innate immunity associated surveillance cells such as dendritic (DC) and 
natural killer (NK) cells from SSc patients appear to be in a hyper-activated status, prone to stimulate Th2 
skewed T-cell activation (34-36). Innate immune responses are mediated, in part, by Toll-like receptors 
(TLRs), which are evolutionarily conserved receptors for foreign pathogen-associated molecular patterns. 
Activation of TLR4 in SSc skin and lungs appears to increase collagen synthesis and enhance TGFβ 
sensitivity. Mice harboring a mutated TLR4 effectively have reduced skin fibrosis in the bleomycin-
induced model (37). TLR4 knockout also attenuates skin and lung fibrosis in the bleomycin-induced model, 
and hypodermal fibrosis in the Tsk1 model (TLR4-/-;Tsk/+mice). In the TLR4-/- mice reduced inflammatory 
cytokine expression, abrogated IL-6 expression in fibroblasts, endothelial cells, and immune cells are 
recognized (38). 
Aberrant activation of the adaptive immune system is evidenced by alterations in T- and B-cells. The 
presence of autoantibodies suggests abnormalities in the B-cell compartment (39). Microarray data on SSc 
skin reveal a clear B-cell signature (40) and SSc patients have a higher number of naïve B-cells with 
increased expression of activation markers (CD95) in memory B-cells. B-cell activating factor (BAFF) is 
expressed in the B-cell lineage and further activates B cells. In the bleomycin induced lung fibrosis model, 
BAFF levels are increased in the bronchoalveolar space. BAFF neutralization by a soluble receptor 
significantly attenuated pulmonary fibrosis and IL-1β levels (41). Belimumab is monoclonal antibody 
directed against BAFF. A Phase IIa study comparing belimumab/mycophenolate mofetil (MMF) to MMF 
alone is currently ongoing in dcSSc patients (NCT01670565). 
In systemic sclerosis, lesional T-cells show a Th2 profile, with increased expression of profibrotic 
interleukin 4 (IL-4) (42). The specific reason for this preferred T cell profile is unknown. Of interest, the 
adhesion receptor DNAX accessory molecule-1 (DNAM-1) is present on a subset of T-cells and is 
overexpressed in SSc skin.  Bleomycin-treated Dnam1-/- mice have significantly decreased numbers of T-
cells in lesional skin, reduced TNF-α and IL-6 levels and appear protected from skin fibrosis development, 
indicating the regulatory role of DNAM-1 in T-cell activation and cytokine release. A DNAM-1 
neutralizing mAb has potent antifibrotic properties (43).  
The relationship between vascular changes and inflammation in the onset of SSc is unclear. Inflammatory 
cell migration is at least partially dependent on tissue exit of the cells through the vascular barrier. The 
interaction between leukocytes and the endothelium is mediated by the interaction between P-, E- and L-
selectins and the leukocyte adhesion receptor P-selectin glycoprotein ligand-1 (PSGL-1). PSGL-1 deficient 
mice were recently described as a model of progressive SSc with features of inflammation and 
autoimmunity, skin and lung fibrosis, microvasculopathy and internal organ involvement (44). From 3 
months onwards, skin abnormalities are observed with superficial skin ulcers with minimal inflammatory 
infiltrates. With increasing age, the ulcers lesions grow and are accompanied by marked fibrosis and 
lipoatrophy in the underlying dermis. There is a significant reduction in the dermal blood vessel number. 
SPGL-1 deficiency results in increased activation state of skin macrophages, an increased number of DCs, 
an imbalance in Teff/Treg cells, increased Th1, Th2 and Th17 cells with production of IL-5, IFN-γ and IL-
17 and heightened proinflammatory cytokine production (IL-6, IL-22, IL-13).  Sera from PSGL-1 deficient 
mice recognize several autoantigens (anti-topoisomerase I, anti-Sm, anti-U1RNP, anti-Jo1, anti-SSA/Ro), 
which can be co-expressed within one individual and with increasing levels with age. The mice also have 
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renal abnormalities, which at young (1.5-3 months) age only occur in females and consist of perivascular 
infiltrates with sclerotic glomeruli and tubularization of Bowman’s capsules with evidence of renal 
infarctisation. With advancing age (12-24 months) females and males are equally affected. The lungs show 
progressive interstitial cellularity and thickened interstitium, occurring from 1.5-3 months onwards. At the 
age of 12-24 months, 55-65% of mice have pulmonary pathology resembling NSIP, associated 
vasculopathy with media thickening. Despite the absence of this selectin-interacting molecule, cell 
migration does not seem dramatically impaired and its effects may be associated more with loss of 
tolerance and lack of regulatory T-cells due to loss of PSGL-1 – Syk signaling in dendritic cells (44).  
Effector cells in fibrosis 
Different cells types appear to contribute to the fibrotic outcome of SSc. A key cellular player in this 
process is the tissue-resident fibroblast.  Increased resistance to apoptosis, transdifferentiation into 
myofibroblasts, excessive collagen production and reduced cell turnover characterize SSc fibroblasts. 
Myofibroblasts are activated fibroblasts, expressing the marker α smooth muscle antigen (αSMA). 
Representing an intermediate stage between fibroblast and smooth muscle phenotype, these cells combine 
features of both cell types and are critical for connective tissue contraction and remodeling. Besides 
fibroblasts and myofibroblasts, various other cell types have been suggested to play a role in SSc and 
contribute to the fibrotic process.  
The specific role of the epithelial cells in the process of fibrosis is still subject of ongoing debate. Epithelial 
cells of different origins have been shown to have the capacity to undergo epithelial-mesenchymal 
transition (EMT), with loss of epithelial markers (e.g. E-cadherin) and gain of mesenchymal markers 
(collagen production, increased mobility) (45) but the in vivo relevance of EMT in pulmonary fibrotic 
pathology remains controversial (51-53).  Other cells types involved may be endothelial cells, pericytes and 
fibrocytes. Endothelial-mesenchymal transition (EndoMT) has been documented but its role in Ssc is 
unclear (46). In early SSc, vascular pericytes (specialized mesenchymal cells, associated with small vessel 
walls) appear activated and express markers suggesting a transitional stage to myofibroblast 
transdifferentiation (47). Finally, bone marrow-derived fibroblast precursors, CD34+ fibrocytes, circulate 
in small numbers in peripheral blood and are thought to play a role in pathologic fibrotic conditions (48). 
Cell migration as contributing mechanism has also been suggested for Sox2-expressing skin progenitor 
cells that were demonstrated to play a role in bleomycin-induced scleroderma and are recruited to fibrotic 
lesions in a CTGF-dependent manner (49).  As progression of skin fibrosis is characterized by loss of 
hypodermal adipose tissue, recent work has focused on intradermal adipocytes. Cell fate mapping studies 
using an adiponectin promoter-driven Cre recombinase transgenic construct, have provided evidence that 
dermal myofibroblasts in bleomycin-induced skin fibrosis can originate from adiponectin-positive 
intradermal progenitors. These progenitors were found in the lesional dermis, lost their adipocyte markers 
and gained mesenchymal markers, in a process of adipocyte-to-myofibroblast transition (50).  These 
findings shed new light on the phenomenon of loss of adipose tissue, reorienting it from a mere symptom to 
a pathogenic event, providing an interesting new therapeutic target (51). 
Signaling pathways in fibrosis 
The behavior of the cellular compartment is likely modulated by the presence of numerous soluble 
mediators, such as TGFβ, CTGF, PDGF, monocyte chemotactic protein 1 (MCP-1), ET-1 and serotonin (5-
hydroxytryptamin- 5HT), which are present at increased levels in SSc. TGFβ is considered the master 
regulator of fibrosis. Not only fibroblasts and myofibroblasts, but also platelets and innate (monocytes and 
macrophages) and adaptive (T-cells) immune cells can produce TGFβ (2). Other pathways associated with 
tissue fibrosis include bone morphogenetic protein signaling (BMP, member of the TGFβ superfamily), 
wingless (Wnt), Notch and hedgehog signaling (52-55). Not surprising, these are examples of typical 
morphogenic pathways that play a role extending from early developmental patterning to tissue 
development, differentiation and growth, but also homeostasis, physiological and pathological remodeling. 
As mentioned above, the current paradigm supports an initial environmental agent that, in a genetic 
susceptible individual, triggers vasculopathy and an immune response that will subsequently initiate repair 
mechanisms. As adequate confinement is lacking however, these processes result in fibrosis. In this 
concept, developmental pathways are key processes to study, and steering of these programs could offer the 
required confinement and limitation of initiated repair mechanisms, resulting in regeneration. 
Wnt signaling 
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WNTs are lipid-modified glycoproteins that bind to Frizzled receptors. In association with low-density 
lipoprotein receptor-related protein-5 or -6 co-receptors, the canonical Wnt cascade with its key mediator β-
catenin is activated (56). Recent data define a key pro-fibrotic role for the Wnt signaling pathway in the 
pathophysiology of systemic sclerosis skin (57) and lung fibrosis (58). Both experimental skin (59, 60) and 
lung fibrosis (61, 62) are largely Wnt-dependent. Modulators of the Wnt signaling pathway activity appear 
promising yet challenging therapeutic targets (63). 
Wnt10b-transgenic mice show progressive dermal fibrosis and were proposed as a mouse model of systemic 
sclerosis (64). FABP4-Wnt10b-tg mice harbor the WNT-10b gene under the control of the fatty acid-
binding protein (FABP) 4 promoter, resulting in ectopic WNT-10b expression in both white and brown 
adipose tissue and bone marrow. At 6 months of age, Wnt 10b-transgenic mice show spontaneous dermal 
fibrosis with loss of adipose tissue and reduced PPAR-γ expression. FABP4-driven ectopic expression of 
Wnt10b results in TGFβ-independent (no difference in pSMAD2, no effect of Alk5 inhibition) upregulation 
of collagen expression and deposition, leading to the replacement of hypodermal fat by fibrous tissue, 
resulting in increased dermal thickness with increased number of myofibroblasts and mast cells. From a 
therapeutic point of view, modulation of Wnt signaling has gained increasing attention and momentum. 
Inactivation of tankyrases 1 and 2 (TNKS-1 and TNKS-2) inhibits canonical Wnt signaling by preventing 
the proteasomal degradation of axin, resulting in the degradation of the key pathway mediator β-catenin. 
Tankyrase inactivation prevented both bleomycin-induced dermal thickening and adenoviral overexpression 
of TβRI-driven (AdTβR) skin fibrosis, without evidence for toxicity. Tankyrases might be candidates for 
targeted therapies in SSc (65). Two pharmaceutical inhibitors of downstream canonical Wnt signaling, 
PKF118-310 and ICG-001, demonstrated beneficial effects both in preventing and reversing bleomycin-
induced dermal fibrosis (59). Furthermore, the Wnt antagonists DKK1 and SFRP1 are downregulated by 
promoter hypermethylation in SSc patients. Inhibition of DNA methyltransferases using 5-aza-2'-
deoxycytidine resulted in normalization of the expression levels of both antagonists and effectively 
ameliorated experimental fibrosis. These data demonstrate that targeting epigenetic alterations can have 
translational implications (66). Reduction of both canonical and non-canonical Wnt ligand secretion by 
fibroblasts through inactivation of evenness interrupted (EVI), a multipass transmembrane protein localized 
in the Golgi and at the cell surface, reduces experimental fibrosis by combined inhibition of canonical and 
non-canonical Wnt signaling in the mouse models of bleomycin-induced and AdTβR -induced fibrosis (67). 
All these accumulating data highlight the critical role of Wnt signaling in the fibrotic process while at the 
same time identifying the need for translational validation of animal model data sets and providing support 
for further dissection of the Wnt cascades’ roles in SSc. 
TGFβ signaling 
As TGFβ is a pleiotropic cytokine and growth factor involved in many different homeostatic and 
pathological processes, attention of the research community has further shifted towards key players in the 
associated signaling pathway not only to understand the fine details of fibrosis but also to eventually 
discover more specific targets for therapeutic intervention. For instance, transgenic mice overexpressing the 
TGFβ coreceptor CD109 in the epidermis, are protected from bleomycin-induced skin fibrosis, suggesting 
that CD109 inhibits TGFβ signaling, regulates dermal-epidermal interactions and should be considered as a 
potential molecular target for therapeutic interventions (68).  
Soluble guanylate cyclase (sGC) catalyzes the production of cyclic guanosine monophosphate (cGMP) 
from guanosine triphosphate. Riociguat, a stimulator of sGC, was recently approved as a novel, effective 
and well-tolerated drug for the treatment of pulmonary arterial hypertension (PAH) (69, 70). 
Pharmaceutical GC stimulation can inhibit TGFβ-induced fibroblast activation and ameliorate bleomycin-
induced skin fibrosis (71). Recent work added strength to these findings and demonstrated that riociguat in 
doses of 1 and 3 mg/kg twice a day has potent dose-dependent anti-fibrotic properties in vitro and in vivo in 
3 different mouse models of skin fibrosis (bleomycin-induced skin fibrosis, chronic graft-versus-host 
(cGVHD) model and Tsk1 mice). Riociguat also ameliorated fibrosis of the gastrointestinal tract in the 
cGVHD model. These findings position riociguat as an interesting therapeutic candidate for the treatment 
of SSc. A randomized, placebo-controlled phase II study with riociguat in patients with SSc is currently 
ongoing (NCT02283762) (72).  
Nintedanib is a tyrosine kinase inhibitor, recently approved in the EU for the treatment of idiopathic 
pulmonary fibrosis (IPF). In vitro, nintedanib reversed the activated state of SSc fibroblasts. In vivo, 
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nintedanib had potent antifibrotic effects in the bleomycin-induced skin fibrosis model, the murine cGVHD 
model and in Tsk1 mice, providing strong experimental evidence for clinical trials with nintedanib in SSc 
(73). Tribbles homologue 3 (TRB3) is a pseudokinase that modifies the activation of various intracellular 
signaling pathways. Recently, TRB3 was shown to be a novel profibrotic mediator in SSc, downstream of 
TGFβ, with increased expression both in human SSc fibroblasts and mouse models of fibrosis.  Knockdown 
of TRB3 reduced the profibrotic effects of TGF-β both in vitro and in vivo in the bleomycin- induced and 
TβRICA mouse model (74). 
Heat shock proteins (Hsps) are a family of molecular chaperones upregulated in response to cellular stress. 
Most Hsp recognize non-native proteins, preventing their irreversible aggregation. Furthermore, they 
modulate antigen processing and presentation and interact with different kinases and transcription factors. 
Hsp90 plays a central role in folding and conformational stabilization of TGFβ receptors (TβRI and TβRII) 
and Src kinases, intracellular mediators of the profibrotic TGFβ-effects. Hsp90 is upregulated in SSc skin 
and mouse models of skin fibrosis. Inhibition of Hsp90, accelerating ubiquitination and proteasomal 
degradation of TGFβR and Src, inhibited canonical TGFβ signaling and completely prevented the 
profibrotic effects of TGFβ both in vitro and in different in vivo models of fibrosis (bleomycin-induced 
dermal fibrosis, Tsk1 mice, TβRICA mice) without indications of toxicity. Hsp90 inhibitors are currently in 
clinical trials for oncological indications and are possible interesting targets in SSc clinical research (75).  
A short critical perspective on therapeutic targeting 
The interplay between different signaling pathways as well as the distinct disease features in SSc remains 
incompletely understood. In recent years, multiple pathways have been targeted in experimental fibrosis 
models, often with promising and spectacular clinical results. Besides the accepted central role of TGFβ 
signaling, other developmental pathways such as Notch (53), hedgehog (55) and Wnt signaling (54) have 
been investigated and appear to play biologically relevant roles.  Likewise, targeting other pathways e.g. 
the serotonin pathway (76), the cannabinoid system (77) and endothelin-dependent signaling (77) also 
successfully prevented and/or treated bleomycin-induced fibrosis. Inhibition of downstream kinase activity 
targeting Abelson (Abl) tyrosine kinase using imatinib (78), Janus kinase 2 (JAK2) (79) or Jun N-terminal 
kinase (80) resulted in inhibition of lung and/or skin fibrosis in the bleomycin-induced model. However, 
translation of these preclinical therapeutic targets to the clinical practice does not appear evident with both 
bosentan (81) and imatinib (82), targeting endothelin and Abl-kinase respectively, proven not to be 
effective in the treatment of lung fibrosis in large randomized placebo-controlled trials. Recent work has 
suggested that this discrepancy might be related to different activation levels of various drug targets in 
different mouse models and suggests that animal models for proof-of-concept studies should be selected 
based on a similar activation level and expression pattern of drug targets as in human SSc (83). Finally, 
interference with morphogen pathways carries the inherent risk of interference with stem cell regeneration, 
potentially complicating their use. Recently it was shown that combination therapies with low doses of 
Hedgehog/Wnt inhibitors or Hedgehog/Notch inhibitors demonstrated additive antifibrotic effects, were 
well tolerated and did not result in a reduction of intestinal stem cell numbers, providing a rationale to 
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